First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group

Haematologica

Volumn 98, Issue 10, 2013, Pages 1563-1570

  Arranz, Reyes ^a   García Noblejas, Ana ^a   Grande, Carlos ^b   Cannata Ortiz, Jimena ^a   Sánchez, José J ^c   García Marco, José Antonio ^d   Aláez, Concepción ^e   Pérez Calvo, Javier ^f   Martínez Sánchez, Pilar ^b   Sánchez González, Blanca ^g   Canales, Miguel Angel ^h   Conde, Eulogio ⁱ   Martín, Alejandro ^j   Arranz, Eva ^a   Terol, María José ^k   Salar, Antonio ^g   Caballero, Dolores ^j  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL MORALES MESEGUER   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^e Clinica Moncloa   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IBRITUMOMAB TIUXETAN; METHOTREXATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; BACTERIAL INFECTION; BLEEDING; CANCER REGRESSION; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; DEATH; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FAILURE FREE SURVIVAL; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; KIDNEY DISEASE; LEUKOPENIA; LUNG ASPERGILLOSIS; LUNG DISEASE; MALE; MANTLE CELL LYMPHOMA; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PERSONALITY DISORDER; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMOCYSTOSIS; PROGRESSION FREE SURVIVAL; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; METHOTREXATE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84884961372     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.088377     Document Type: Article

References (37)

1. Swerdlow SH, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Fourth Edition. Lyon, France: IARC Press; 2008.
2. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002;20(5):1288-94.
3. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-92.
4. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009;27(36): 6101-08.
5. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23(28):7013-23.
6. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, et al. Longterm progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivopurged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood. 2008;112(7): 2687-93.
7. Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol. 2012;156(3):346-53.
8. Lefrère F, Delmer A, Suzan F, Levy V, Belanger C, Djabarri M, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves eventfree survival in mantle cell lymphoma: a prospective study. Leukemia. 2002;16(4): 587-93.
9. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximabpurged stem cell autografting (R-HDS regimen). Blood. 2003;102(2):749-55.
10. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105 (7):2677-84.
11. Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/ cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol. 2010;150(2):200-8.
12. Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol. 2012; 158(3):355-62.
13. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH, et al. Treatment of older patients with mantlecell lymphoma. N Engl J Med. 2012;367 (6):520-31.
14. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117(1):45-52.
15. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352(5):441-9.
16. Bishton MJ, Leahy MF, Hicks RJ, Turner JH, McQuillan AD, Seymour JF. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin/s lymphoma who had previously responded to iodine-131-rituximab. Ann Oncol. 2008;19(9): 1629-33.
17. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26(32):5156-64.
18. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2009;27(31):5213-8.
19. Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A, Kahl BS, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol. 2012;30(25): 3119-26.
20. Jurczak W, Giza A, Zimowska-Curylo D, Zimowska-Curylo D, Sobocinski M, Stella-Holowiecka B, et al. 90Y-Zevalin(r) (90Yibritumomab tiuxetan) radioimmunotherapy (RIT) consolidation in mantle cell lymphoma (MCL) patients, not ilegible for intensive therapy protocols. American Society of Hematology Annual Meeting. 2007. [Abstract 110] Dec; Atlanta: 4497.
21. Kolstad A, Laurell A, Jerkeman M, Gronbaek K, Elonen E, Räty R, et al. Nordic MCL3 study: zevalin combined with high-dose chemotherapy followed by autologous stem cell support as late intensification for mantle cell lymphoma (MCL) patients < 66 years not in CR after induction chemoimmunotherapy: no benefit of zevalin. 2012. [Abstract 747] Dec; Atlanta: 747.
22. Beaven A, Rizzieri D, Zachary Powell ZL, Li Z, Alton P, Warzecho J, et al. High complete response rates with dose dense/dose intense chemotherapy plus radioimmunotherapy in high risk diffuse large B cell and mantle cell lymphoma. American Society of Hematology Annual Meeting. 2011. [Abstract] Dec 118; San Diego: 2681a
23. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Arlie House, Virginia, November 1997. Histopathology. 2000;36(1):69-86.
24. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report on an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol. 1999;17(4): 1244.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc. 1958;53:457-81.
26. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing rosks: new representation of old estimatiors. Stat Med. 1999;18(6):695-706.
27. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood. 2008; 111(2):558-65.
28. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) Increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). American Society of Hematology Annual Meeting. 2012. [Abstract] Dec 120; Atlanta: 151.
29. Barista I, Cabanillas F, Romaguera JE, Khouri IF, Yang Y, Smith TL, et al. Is there an increased rate of additional malignancies in patients with mantle cell lymphoma?. Ann Oncol. 2002;13(2):318-22.
30. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008; 26(32):5156-64.
31. Zinzani PL, Derenzini E, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, et al. Longterm efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). Ann Oncol. 2012;23(3):805-7.
32. Czuczman MS, Emmanouilides C, Darif, Witzig TE, Gordon LI, Revell S M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007; 25(27):4285-92.
33. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105(12):4576-82.
34. Guidetti A, Carlo-Stella C, Ruella M, Miceli R, Devizzi L, Locatelli SL, et al. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer. 2011;117(22):5074-84.
35. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatmentrelated myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21(5):897-906.
36. Pedersen-Bjergaard J, Specht L, Larsen SO, Ersbøll J, Struck J, Hansen MM, et al. Risk of therapy related leukaemia and preleukaemia after Hodgkin's disease: Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet. 1987; 2(8550):83-8.
37. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008; 22(2):240-8.